ArticleInternational journal of molecular sciences2019
Redifferentiation of Articular Chondrocytes by Hyperacute Serum and Platelet Rich Plasma in Collagen Type I Hydrogels.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Short-Term Outcomes of Percutaneous Trephination with a Platelet Rich Plasma Intrameniscal Injection for the Repair of Degenerative Meniscal Lesions. A Prospective, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study.International journal of molecular sciences · 2019Trial
- DNA-encoded dynamic hydrogels for 3D bioprinted cartilage organoids.Materials today. Bio · 2025Review
- Infiltration therapy in the context of cartilage surgery.Archives of orthopaedic and trauma surgery · 2024Review
- Collagen and Alginate Hydrogels Support Chondrocytes Redifferentiation In Vitro without Supplementation of Exogenous Growth Factors.ACS omega · 2024Article
- Human Chondrocytes, Metabolism of Articular Cartilage, and Strategies for Application to Tissue Engineering.International journal of molecular sciences · 2023Review
- Collagen-Based Hydrogels for Cartilage Regeneration.Orthopaedic surgery · 2023Review
- Hypoxia Preconditioned Serum (HPS) Promotes Proliferation and Chondrogenic Phenotype of Chondrocytes In Vitro.International journal of molecular sciences · 2023Article
- Application of Alginate Hydrogels for Next-Generation Articular Cartilage Regeneration.International journal of molecular sciences · 2022Review
- Meniscus cell regional phenotypes: Dedifferentiation and reversal by biomaterial embedding.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2021Article
- Regenerative Potential of Blood-Derived Products in 3D Osteoarthritic Chondrocyte Culture System.Current issues in molecular biology · 2021Article
- Strategies to Modulate the Redifferentiation of Chondrocytes.Frontiers in bioengineering and biotechnology · 2021Review
- Atelocollagen promotes chondrogenic differentiation of human adipose-derived mesenchymal stem cells.Scientific reports · 2020Article
- PRP and BMAC for Musculoskeletal Conditions via Biomaterial Carriers.International journal of molecular sciences · 2019Review
- Blood-Derived Products for Tissue Repair/Regeneration.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Matrix-assisted autologous chondrocyte transplantation (MACT) for focal articular cartilage defects often fails to produce adequate cartilage-specific extracellular matrix in vitro and upon transplantation results in fibrocartilage due to dedifferentiation during cell expansion. This study aimed to redifferentiate the chondrocytes through supplementation of blood-products, such as hyperacute serum (HAS) and platelet-rich plasma (PRP) in vitro. Dedifferentiated monolayer chondrocytes embedded onto collagen type I hydrogels were redifferentiated through supplementation of 10% HAS or 10% PRP for 14 days in vitro under normoxia (20% O₂) and hypoxia (4% O₂). Cell proliferation was increased by supplementing HAS for 14 days (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.